Axinn Successful in Protecting FDA Approval of Generic Versions of Otsuka’s Abilify
April 29, 2015
A team of attorneys from Axinn successfully intervened on behalf of Zydus Pharmaceuticals on the side of the U.S. Food and Drug Administration in the U.S. District Court in Maryland to oppose Otsuka Pharmaceuticals’ motion for a temporary restraining order. Otsuka sought the order to prohibit FDA from granting approvals for any generic versions of Otsuka’s $4 billion prescription brand drug aripiprazole, which Otsuka markets under the name Abilify®.
Otsuka claimed a seven-year market exclusivity for Abilify under the orphan drug designation, as the FDA approved Abilify for the use in the treatment of Tourette’s disorder in pediatric patients. Otsuka also alleged that generic competition is likely to cause the drug maker irreparable harm. Today, U.S. District Judge George Hazel denied Otsuka’s motion for a temporary restraining order, allowing generic versions of Abilify to enter the market. The court’s ruling will provide significant cost savings for consumers as generic competition will cause drug prices to decrease. The ruling also reaffirms FDA’s discretion in allowing generics to carve out indications from their labels that are protected by marketing exclusivity.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
National Bar Association 100th Annual Convention and Exhibits
Sponsorship
Antitrust
Keeping Pace: Updates in Cartel Enforcement
Webinar
Antitrust
GCR Live: Law Leaders Europe 2025
Speaking Engagement
Antitrust
Navigating the Hart-Scott-Rodino Act in 2025
Webinar
Antitrust
AHLA Annual Meeting 2025
Speaking Engagement
Antitrust
State by State, Pre-Merger Notifications Expand
Axinn Viewpoints
Antitrust
FTC claims diverging market from EU in Mars/Kellanova clearance
Media Mentions
Keeping an Eye on the Ball: America First Antitrust Weighs in on the “Uniquely American System of Scholar Athletics”
Axinn Viewpoints
Antitrust
Wait, We Have To Tell Who? What You Need To Know About State Premerger Notifications
Podcast
MBK | MSK Fellowship Summit 2025
Sponsorship
Antitrust